Circulating Fractalkine Levels Predict the Development of the Metabolic Syndrome
Table 5
Multiple logistic regression analysis of baseline fractalkine quartiles in the prediction of MetS and its components at year 2: ORs ().
ORs (95% CI)
Q1
Q2
Q3
Q4
for trend
≤0.28 ng/mL
0.28–0.43 ng/mL
0.43–0.64 ng/mL
0.64 ng/mL
MetS
Model 1
1
1.61 (0.73–3.52)
2.81 (1.17–6.74)
7.05 (2.26–18.00)
<0.001
Model 2
1
1.64 (0.75–3.63)
2.89 (1.19–6.98)
7.18 (2.28–18.59)
<0.001
Model 3
1
1.80 (0.79–4.10)
2.67 (1.08–6.59)
5.31 (1.65–14.09)
0.016
Model 4
1
1.81 (0.79–4.16)
2.65 (1.06–6.61)
5.17 (1.60–13.74)
0.019
Model 5
1
1.67 (0.75–3.73)
2.86 (1.17–6.99)
5.73 (1.79–14.34)
0.007
Model 6
1
1.50 (0.66–3.40)
2.64 (1.06–6.56)
5.94 (1.85–15.09)
0.006
Central obesity
Model 1
1
1.46 (0.75–2.84)
2.44 (1.19–4.99)
5.00 (2.17–11.50)
<0.001
Model 2
1
1.43 (0.73–2.80)
2.37 (1.15–4.87)
4.83 (2.09–11.19)
<0.001
Model 3
1
1.28 (0.62–2.65)
1.60 (0.73–3.48)
2.46 (0.99–6.03)
0.146
Model 4
1
1.46 (0.69–3.06)
1.51 (0.72–2.99)
2.18 (0.95–6.01)
0.126
Model 5
1
1.44 (0.73–2.84)
2.34 (1.13–4.84)
4.17 (1.78–9.79)
0.004
Model 6
1
1.41 (0.72–2.80)
2.36 (1.14–4.91)
4.58 (1.96–10.72)
0.001
Elevated BP
Model 1
1
0.54 (0.29–1.11)
1.10 (0.59–2.05)
1.08 (0.59–2.01)
0.069
Model 2
1
0.53 (0.28–1.10)
1.09 (0.58–2.07)
1.03 (0.55–1.93)
0.078
Model 3
1
0.54 (0.28–1.12)
1.03 (0.54–1.97)
0.86 (0.45–1.64)
0.150
Model 4
1
0.49 (0.27–1.04)
0.94 (0.49–1.80)
0.77 (0.40–1.48)
0.118
Model 5
1
0.53 (0.28–1.11)
1.08 (0.57–2.04)
0.90 (0.47–1.72)
0.105
Model 6
1
0.52 (0.28–1.08)
1.05 (0.55–1.99)
0.95 (0.50–1.80)
0.085
Hyperglycemia
Model 1
1
1.65 (0.82–3.32)
1.87 (0.92–3.79)
3.53 (1.60–7.81)
0.014
Model 2
1
1.66 (0.82–3.35)
1.89 (0.93–3.83)
3.61 (1.63–8.02)
0.013
Model 3
1
1.69 (0.83–3.43)
1.83 (0.90–3.74)
3.35 (1.49–7.55)
0.029
Model 4a
1
1.71 (0.84–3.51)
1.86 (0.90–3.84)
3.40 (1.49–7.75)
0.029
Model 5
1
1.68 (0.83–3.41)
1.84 (0.90–3.75)
3.07 (1.24–7.14)
0.071
Model 6
1
1.69 (0.83–3.43)
1.92 (0.94–3.92)
3.57 (1.60–7.99)
0.016
Hypertriglyceridemiab
Model 1
1
1.37 (0.71–2.64)
1.82 (0.93–3.55)
2.69 (1.33–5.44)
0.038
Model 2
1
1.36 (0.70–2.62)
1.78 (0.91–3.50)
2.63 (1.30–5.34)
0.046
Model 3
1
1.38 (0.71–2.68)
1.72 (0.87–3.38)
2.28 (1.01–4.69)
0.141
Model 4
1
1.09 (0.55–2.17)
1.33 (0.65–2.69)
1.75 (0.83–3.71)
0.460
Model 5
1
1.36 (0.70–2.63)
1.77 (0.90–3.47)
2.33 (1.03–4.79)
0.113
Model 6
1
1.33 (0.67–2.63)
1.82 (0.91–3.64)
2.46 (1.19–5.11)
0.080
Low HDL-cb
Model 1
1
0.84 (0.34–2.10)
0.93 (0.38–2.32)
1.51 (0.58–3.98)
0.595
Model 2
1
0.86 (0.34–2.15)
0.96 (0.38–2.38)
1.59 (0.60–4.24)
0.550
Model 3
1
0.86 (0.34–2.16)
0.95 (0.38–2.38)
1.50 (0.56–4.05)
0.665
Model 4
1
0.92 (0.37–2.34)
1.04 (0.41–2.64)
1.69 (0.61–4.63)
0.603
Model 5
1
0.85 (0.34–2.14)
0.96 (0.39–2.40)
1.64 (0.61–4.42)
0.532
Model 6
1
0.92 (0.37–2.34)
1.05 (0.42–2.64)
1.78 (0.66–4.80)
0.502
OR: odds ratio, CI: confidence interval. Model 1: adjusted for age, sex. Model 2: further adjusted for education attainment, smoking, alcohol, and drinking based on model 1. Model 3: further adjusted for visceral fat based on model 2. Model 4: further adjusted for CRP based on model 3. Model 5: further adjusted for HOMA-IR based on model 2; for hyperglycemia: further adjusted for FINS based on model 2. Model 6: further adjusted for TG and HDL-c based on model 2. Not adjusted for itself. Abbreviations as in Table 1.
